Monitoring of Inflammatory Conditions

计划入组 664 人 · 首次发布于 2022 年 7 月 14 日

Intestinal Bacteria and Ocular Inflammatory Disease

计划入组 131 人 · 首次发布于 2013 年 5 月 21 日

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

计划入组 147 人 · 首次发布于 2006 年 5 月 29 日

Sulfacetamide(Avar, Blephamide, Cetamide, FML-S, Isopto Cetamide, Klaron, Ovace, Plexion, Sulf-10, Sumadan Wash, Sumaxin)

C₈H₁₀N₂O₃S

anti-inflammatory agents (ocular inflammation)

ShK-Ocular

Ocular Therapeutix

United States

Ocular Therapeutix, Inc.

United States

Refocus Group, Inc.

United States

FDA-Approved Cimerli: First Interchangeable Biosimilar for Ocular Conditions Now Available

Tacrolimus Eye Drops with Cyclodextrins Show Improved Safety and Compliance in Ocular Inflammatory Pathologies

FDA Approves Celltrion's Avtozma, a Tocilizumab Biosimilar, for Multiple Inflammatory Conditions